deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT01653756

A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose, Cross-Over, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects Undergoing Allergen Challenge

Sponsor: SecuraBio

Conditions Asthma
Interventions IPI-145, a PI3K Inhibitor Placebo to match IPI-145
Updated 10 times since 2017 Last updated: Mar 15, 2021 Started: Jul 31, 2012 Primary completion: Aug 31, 2014 Completion: Sep 30, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Asthma and is currently completed. SecuraBio leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshotCompleted~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshotCompleted~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshotCompleted~Nov 2018 – ~Jan 2021 · 26 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshotCompleted~Apr 2021 – ~Jul 2024 · 39 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Apr 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE2

▶ Show 5 earlier versions

  1. Nov 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jun 2018 — Nov 2018 [monthly]

    Completed PHASE2

  3. Aug 2017 — Jun 2018 [monthly]

    Completed PHASE2

  4. Feb 2017 — Aug 2017 [monthly]

    Completed PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • SecuraBio
Data source: SecuraBio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations